Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
Year: 2023
Type: article
Abstract: BACKGROUND: The phase III MONALEESA-3 trial included first- (1L) and second-line (2L) patients and demonstrated a significant overall survival (OS) benefit for ribociclib + fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) in the final protocol-specified and exploratory (longer follow-up) OS analyses. At the time of these analyses, the full OS benefit of 1L ribociclib was not completely characterized because the median OS (mOS) was not reached. As CDK4/6 inhibitor (CDK4/6i) + endocrine therapy (ET) is now a preferred option for 1L HR+/HER2- ABC, we report an exploratory analysis (median follow-up, 70.8 months; 14.5 months longer than the prior analysis) to fully elucidate the OS benefit in the MONALEESA-3 1L population. METHODS: Postmenopausal patients with HR+/HER2- ABC were randomized 2:1 to 1L/2L fulvestrant + ribociclib or placebo. OS in 1L patients (de novo disease or relapse > 12 months from completion of [neo]adjuvant ET) was assessed by Cox proportional hazards model and Kaplan-Meier methods. Progression-free survival 2 (PFS2) and chemotherapy-free survival (CFS) were analyzed. MONALEESA-3 is registered with ClinicalTrials.gov (NCT02422615). RESULTS: At data cutoff (January 12, 2022; median follow-up time, 70.8 months), mOS was 67.6 versus 51.8 months with 1L ribociclib versus placebo (hazard ratio (HR) 0.67; 95% CI 0.50-0.90); 16.5% and 8.6% of ribociclib and placebo patients, respectively, were still receiving treatment. PFS2 (HR 0.64) and CFS (HR 0.62) favored ribociclib versus placebo. Among those who discontinued treatment, 16.7% and 35.0% on ribociclib or placebo, respectively, received a subsequent CDK4/6i. No new safety signals were observed. CONCLUSIONS: This analysis of MONALEESA-3 reports the longest mOS thus far (67.6 months) for 1L patients in a phase III ABC trial. These results in a 1L population show that the OS benefit of ribociclib was maintained through extended follow-up, further supporting its use in HR+/HER2- ABC.
Source: Breast Cancer Research
Institutions: Universitair Ziekenhuis Leuven, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinikum Erlangen, BC Cancer Agency, Centre Hospitalier Universitaire de Liège, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Seoul National University, Seoul National University Hospital, Masaryk Memorial Cancer Institute, Fondazione IRCCS Istituto Nazionale dei Tumori, Universidad Complutense de Madrid, Centro de Investigación Biomédica en Red de Cáncer, GEICAM – Spanish Breast Cancer Group, Instituto de Investigación Sanitaria Gregorio Marañón, The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Hospital Universitario Virgen Macarena, Highlands Oncology Group, Novartis (Switzerland), University of California, Los Angeles
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: ribociclib, fulvestrant, HR+/HER2- advanced breast cancer, postmenopausal women, first-line therapy, CDK4/6 inhibitors, endocrine therapy, overall survival, progression-free survival, long-term follow-up, treatment discontinuation, treatment-related adverse events, drug safety and tolerability
Open Access status: gold
Estimated APC paid: $3,890
OpenAlex ID: W4386329445
